Biomarker Patient-Selection Radar
Track how biomarkers are used for patient selection, stratification, and treatment assignment in solid tumor oncology trials.
Built from public interventional trial text and a conservative FDA CDx mapping. Threshold fragments and patent-density signals require expert clinical and regulatory review before use — this tool does not recommend patient-selection strategies or companion diagnostic approaches.
Which biomarkers are becoming clinically actionable and commercially important?
Biomarker Patient-Selection Radar tracks which biomarkers are moving from exploratory subgroup use into required enrollment criteria, how thresholds differ across trials, where FDA CDx context exists, and where diagnostic patent-density signals are emerging ahead of or alongside clinical adoption.
Target users
- Diagnostic companies monitoring biomarker adoption and CDx context
- Precision-medicine teams tracking patient-selection trends
- Pharma translational medicine groups bridging biomarker and trial strategy
- Oncology biotech founders building biomarker-stratified programs
- CRO biomarker recruitment teams evaluating eligibility and threshold fragmentation
- CDx strategy teams mapping where diagnostics are ahead of or behind clinical use
Tracked oncology biomarkers
The Solid Tumor Oncology edition tracks biomarker patient-selection contexts across the following and adjacent biomarkers:
- EGFR mutations
- ALK, ROS1, RET, NTRK fusions
- KRAS G12C and KRAS G12D
- BRAF V600E
- HER2 amplification or expression
- PD-L1 expression
- MSI-H / dMMR
- TMB-high
- BRCA1/2 and HRD
- MET exon 14 skipping
- CLDN18.2 expression
- FRα / FOLR1 expression
Biomarker coverage expands as new trial activity and CDx context is detected. Custom biomarker scans are available on request.
How teams use this module
- Track CLDN18.2 expression thresholds across gastric cancer trials and compare CDx context
- Compare FRα and HER2 patient-selection strategies — inclusion, stratification, or exploratory
- Monitor KRAS G12D trial adoption as programs enter active recruitment
- Identify biomarkers where drug development appears ahead of mature CDx context
- Detect threshold fragmentation across trials using the same biomarker
- Generate custom tumor-type biomarker scans for CDx strategy or diligence work
Solid Tumor Oncology Edition
Screen biomarker contexts by role evidence, tumor type, drug context, threshold fragmentation, FDA CDx context, and diagnostic patent-density signals.
- Biomarker pages, context pages, and sponsor views
- Threshold extraction from public trial text
- FDA CDx context mapped conservatively by biomarker and indication
- Conservative CDx and threshold framing — designed for expert review before use
Receive Biomarker Updates by Email
Tell us which biomarker, tumor type, and use case matter to your team. We use this for email updates, CSV delivery preferences, and custom scan follow-up.